This is the authors' abstract. We don't add key points for this paper.
Objective: This study aimed to characterize Amprotab that has been modified chemically, physically, and mechanically using HPMC and citric acid. Methods: The study is divided into two parts: three control formulas and three treatment formulas. Control Formula 1 (without HPMC and citric acid), Control 2 (HPMC 1.5 g without citric acids), Control 3 (citric acid 1.5 g without HPMC), Formula 1 (HPMC 4.5 g and citric acid 4.5 g). By analyzing Fourier Transform Infrared (FTIR), scanning electron microscopy (SEM), swelling, tensile strength, stability (freeze-thaw cycles), X-ray Diffraction (XRD), and Thermogravimetric Analysis (TGA), copolymers modified by Amprotab were characterized. Results: An FTIR analysis revealed that crosslinking of Amprotab was formed in formulas 1, 2, and 3 with prominent C=O ester bonds at peaks of 1730.22 cm-1, 1733.12 cm-1, and 1736.01 cm-1. The surface morphology of the modified cassava amylum CROSSLINKED COPOLYMER (CCA) was coarser. CCA's expanding power is less than that of natural Amprotab, whereas CCA's tensile strength is greater. Conclusion: CCA has a high value for syneresis. XRD analysis revealed that CCA has a crystal diffraction pattern of type B, and TGA analysis revealed that CCA is stable at high temperatures.
No takes yet. Share an insight, caveat, or question.
Sulaiman et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: